Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
This research aims to assess the impact of an interprofessional education program IPEP on healthcare students collaboration skills during their clinical placements in multidisciplinary primary care centers MPCC. The study compares students who receive IPEP during their MPCC placements with those who undergo placements without this program. The IPEP is delivered by trained healthcare professionals within the MPCCs to enhance interprofessional collaboration IPC. The study involves two groups an intervention group where 12 MPCCs participate, each having 3 professionals trained to implement the IPEP for students and a control group of 12 MPCCs where students complete their clinical placements as usual without the IPEP. The trained professionals receive instruction through a train the trainer program led by an educational team before delivering the IPEP. Participants will be observed during their clinical placements, with assessments comparing student scores on the Interprofessional Collaborative Competency Attainment Survey ICCAS before and after placement. Qualitative studies will explore students perceptions and feelings about interprofessional collaboration in both groups. The study duration includes 18 months for quantitative assessments and 24 months for qualitative components.
Actively Recruiting
This research focuses on anxiety experienced by patients receiving palliative care, their families, and healthcare providers. Anxiety in this setting can arise from fears of death, loss of function, or worsening symptoms, contributing to emotional and physical suffering and lowering quality of life. While most anxiety data in palliative care comes from cancer patients, it may affect over 70% of individuals. Researchers aim to evaluate the impact of a serious game designed to educate and reduce anxiety using a playful approach. Participants are randomly assigned to one of two groups one group receives standard care provided by the mobile palliative care team, and the other group receives the same standard care plus access to the serious game SPAMLO-3.0. The game explores palliative care in hospital, home, and nursing home settings through the perspective of a virtual character named Vito, covering topics such as advance directives, home adaptations, and respecting patient choices. Participants have 7 days to complete the game with multiple sessions allowed. Participants are evaluated at the start, on Day 15, and on Day 30. Anxiety levels are measured using the Hospital Anxiety and Depression Scale, along with assessments of quality of life, insomnia severity, performance status, and other measures. Researchers also assess the games acceptability, usability, and completion rates. The study lasts 30 days for each participant, providing time for reflection and potential advance care planning following game participation.
Actively Recruiting
Researchers are conducting an observational, multicenter study focusing on patients with non-small cell lung cancer NSCLC who are starting treatment with approved drugs developed by AstraZeneca or its alliance partners. The study includes three patient groups based on disease stage resectable, unresectable, and metastatic NSCLC. This modular study evaluates these treatments as monotherapy or in combination across various disease stages once European marketing authorization is granted and the drugs are available in the participating countries. Participants receive treatments independently decided by their doctors before joining the study, without any changes made by the research team. The study collects data retrospectively and prospectively on patients who have received, are receiving, or will receive these approved drugs. Each cohort reflects real-world use of AstraZeneca or alliance-developed drugs in different NSCLC stages, with no experimental intervention assigned by the study. During the study, researchers collect information on disease progression, treatment responses, and survival over three years, including measures such as real-world disease-free survival and time to treatment failure. Data on response rates and additional survival outcomes are also gathered. Participants health and treatment outcomes are monitored through routine clinical data collection and follow-up, contributing to a better understanding of these treatments in everyday clinical practice.